NASDAQ:QURE

Uniqure N.v Stock Insider Trading

Healthcare > Biotechnology

Buy QURE

*Your capital is at risk

$46.06

-0.360 (-0.776%)

At Close: Aug 10, 2026

uniQure N.V Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -78.96. In total, the insiders bought 1.29M and sold 485.14K QURE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-78.96
● Buy	1.29M shares
● Sell	485.14K shares
56% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Jun 17, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -78.96. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 11, 2026 Sell	Ordinary Shares S-Sale	Kaye Jack Director	Director	1 993 Value: $53.9K
Jun 11, 2026 Sell	Ordinary Shares S-Sale	O'keefe Kylie Chief Customer & Strat Officer	Officer	15 936 Value: $431.2K
Jun 11, 2026 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	2 726 Value: $73.8K
Jun 11, 2026 Sell	Ordinary Shares S-Sale	Meek David D. Director	Director	1 993 Value: $53.9K
Jun 11, 2026 Sell	Ordinary Shares S-Sale	Springhorn Jeremy P. Director	Director	1 993 Value: $53.9K
Jun 11, 2026 Sell	Ordinary Shares S-Sale	Post Leonard E Director	Director	1 993 Value: $53.9K
Jun 10, 2026 Buy	Stock Option (Right to Buy) A-Award	Balachandran Madhavan Director	Director	13 980 Value: $374.9K
Jun 10, 2026 Buy	Ordinary Shares A-Award	Balachandran Madhavan Director	Director	7 550 Value: $202.5K
Jun 10, 2026 Buy	Stock Option (Right to Buy) A-Award	Jacques Rachelle Suzanne Director	Director	13 980 Value: $374.9K
Jun 10, 2026 Buy	Ordinary Shares A-Award	Jacques Rachelle Suzanne Director	Director	7 550 Value: $202.5K
Jun 10, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Gut Robert Director	Director	2 645 Value: $42.4K
Jun 10, 2026 Buy	Stock Option (Right to Buy) A-Award	Gut Robert Director	Director	13 980 Value: $374.9K
Jun 10, 2026 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	1 780 Value: $46.4K
Jun 10, 2026 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	3 127 Value: $81.4K
Jun 10, 2026 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	2 645 Value: $69.0K
Jun 10, 2026 Buy	Ordinary Shares M-Exempt	Gut Robert Director	Director	2 645 Value: $42.4K
Jun 10, 2026 Buy	Ordinary Shares A-Award	Meek David D. Director	Director	7 550 Value: $202.5K
Jun 10, 2026 Buy	Stock Option (Right to Buy) A-Award	Meek David D. Director	Director	13 980 Value: $374.9K
Jun 10, 2026 Buy	Ordinary Shares A-Award	Gut Robert Director	Director	7 550 Value: $202.5K
Jun 10, 2026 Buy	Ordinary Shares A-Award	Springhorn Jeremy P. Director	Director	7 550 Value: $202.5K
Jun 10, 2026 Buy	Stock Option (Right to Buy) A-Award	Springhorn Jeremy P. Director	Director	13 980 Value: $374.9K
Jun 10, 2026 Buy	Ordinary Shares A-Award	Post Leonard E Director	Director	7 550 Value: $202.5K
Jun 10, 2026 Buy	Stock Option (Right to Buy) A-Award	Post Leonard E Director	Director	13 980 Value: $374.9K
Jun 10, 2026 Buy	Ordinary Shares A-Award	Kaye Jack Director	Director	7 550 Value: $202.5K
Jun 10, 2026 Buy	Stock Option (Right to Buy) A-Award	Kaye Jack Director	Director	13 980 Value: $374.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT UNIQURE N.V.

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas...

Read Full Profile Here